Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(1.09)
# 3,424
Out of 4,814 analysts
27
Total ratings
34.78%
Success rate
-14.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $5.65 | +307.44% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $1.17 | +412.82% | 2 | Dec 20, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $675 → $706 | $595.28 | +18.60% | 4 | Nov 21, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $55.25 | +207.69% | 9 | Nov 7, 2024 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $65 | $4.44 | +1,363.96% | 2 | Aug 26, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $3.93 | +408.91% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $161.93 | +27.22% | 1 | Aug 12, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $62 → $66 | $38.41 | +71.83% | 2 | Aug 8, 2024 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $22 | $1.13 | +1,846.90% | 1 | Oct 3, 2023 | |
| CCCC C4 Therapeutics | Maintains: Outperform | $20 → $10 | $1.39 | +619.42% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $159 → $165 | $170.16 | -3.03% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $11.38 | +427.24% | 1 | Oct 5, 2022 |
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $5.65
Upside: +307.44%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $1.17
Upside: +412.82%
argenx SE
Nov 21, 2024
Maintains: Outperform
Price Target: $675 → $706
Current: $595.28
Upside: +18.60%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $55.25
Upside: +207.69%
Jasper Therapeutics
Aug 26, 2024
Maintains: Outperform
Price Target: $65
Current: $4.44
Upside: +1,363.96%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $3.93
Upside: +408.91%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $161.93
Upside: +27.22%
Mirum Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $62 → $66
Current: $38.41
Upside: +71.83%
Aclaris Therapeutics
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $1.13
Upside: +1,846.90%
C4 Therapeutics
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $1.39
Upside: +619.42%
Feb 9, 2023
Maintains: Outperform
Price Target: $159 → $165
Current: $170.16
Upside: -3.03%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $11.38
Upside: +427.24%